MedTrace Logo

Complications in Pediatric Mechanical Circulatory Assistance: Evaluation of Infection Management.

NCT06464016 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 47

Last updated 2025-01-28

No results posted yet for this study

Summary

Heart failure is a major cause of mortality and morbidity in children. Heart transplantation can significantly improve the prognosis of patients with severe heart failure, but access is limited by a shortage of transplants.

Long-term mechanical circulatory support is a major advance in the management of heart failure and can provide haemodynamic support while awaiting myocardial recovery or heart transplantation. The Berlin Heart (BH) EXCOR is the only long-term support system available for children.

Despite technical and medical advances in circulatory support, infection is a common complication and a major cause of morbidity and mortality in patients on BH.

There are few studies on the management of infection with mechanical support. Current ISHLT (International Society for Heart and Lung Transplantation) recommendations are based on expert opinion and observational studies. Some experts recommend anti-infective therapy until transplantation for specific support infections or for support-associated infections with persistent bacteraemia.

Conditions

  • Heart-Assist Devices
  • Infections
  • Heart Transplant Infection

Interventions

DEVICE

Ventricular Assist Device with Berlin Heart EXCOR

The Berlin Heart® EXCOR is a type of "artificial heart" pump that pulls blood from the ventricle and then sends that blood to the aorta or pulmonary trunc, thereby taking away extra work from the native heart. The device, which comes in several sizes, is not totally implanted inside the body.

Sponsors & Collaborators

  • Hospices Civils de Lyon

    collaborator OTHER

  • Claude Bernard University

    lead OTHER

Principal Investigators

  • Luc Panetta, MD · Hospices Civils de Lyon

Eligibility

Min Age
1 Day
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-04
Primary Completion
2025-10-01
Completion
2025-11-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06464016 on ClinicalTrials.gov